NPCE Earnings

NPCE reported its earnings on 2026-03-03, showcasing a revenue of 26.59M against an estimate of 25.95M, resulting in a 2.46% surprise. The EPS was -0.08, surpassing the expected -0.14 by 42.86%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NPCE's earnings announcement on 2026-03-03, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NPCE's stock price tends to shift by an average of 5.29% in the 10 days leading up to earnings and 2.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate NPCE's annual revenue to reach 22.35M, while the EPS is projected at -0.19. These estimates reflect recent revisions, with revenue estimates revised downward by -0.03% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NPCE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.03%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NPCE's stock price typically moves by 5.29% in the 10 days before its earnings and 2.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.19 and revenue of 22.35M.

NeuroPace's earnings call reveals strong financial performance with significant revenue and gross margin growth, positive adjusted EBITDA, and reduced net loss. The raised revenue and gross margin guidance for 2025 further indicates optimism. Despite increased operating expenses, the strategic focus on RNS and upcoming FDA submissions, combined with favorable analyst sentiment, supports a positive outlook. The Q&A section highlights the potential of generalized epilepsy opportunities and Project CARE's growth contribution, reinforcing positive sentiment. Given these factors, a positive stock price reaction is expected over the next two weeks.